Protocol CY 4031: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tiramsemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)

Trial ID or NCT#

NCT02496767

Status

recruiting iconRECRUITING

Purpose

To assess the safety, tolerability, and efficacy of the study medication, Tirasemtiv, in ALS.

Investigator(s)

Yuen So, MD, PhD
SEND MESSAGE

View on ClinicalTrials.gov